Thinly traded nano cap Protalix BioTherapeutics (NYSEMKT:PLX) is up 18% premarket on modest volume in reaction to 12-month data on pegunigalsidase alfa (PRX-102) from the first 16 Fabry subjects in the open-label Phase 3 BRIDGE switchover study.
At month 12, 16 of 22 enrolled patients who were on a stable regimen of agalsidase alfa [Takeda’s (NYSE:TAK)
Replagal] who switched to pegunigalsidase alfa experienced a mean
improvement in kidney function with a favorable safety profile.
The results were consistent with six-month data announced in about a year ago.
Development is ongoing.
https://seekingalpha.com/news/3506474-protalix-18-percent-premarket-longer-term-prxminus-102-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.